Viridium Pacific Provides Fiscal Q2 Corporate Update
Calgary, Alberta (FSCwire) - Viridium Pacific Group Ltd. (“Viridium” or the “Company”) (TSXV: VIR) (OTCPink: MRRBF) is pleased to provide an update on the Company's accomplishments during the second quarter (ending May 31) of fiscal 2018. Over the past year, Experion Biotechnologies Inc. (“Experion”), a Licensed Producer (“LP”) and wholly owned subsidiary of Viridium, has focused its efforts on attaining Health Canada license approvals, bringing the Company’s indoor facility in Mission BC to full operating status and expanding capacity on the existing property. As well, Experion continued to achieve numerous licensing and commercial development milestones in the quarter.
Mr. Jarrett Malnarich, Viridium CEO, commented, "We have built a solid operational team that has repeatedly proven their ability – and the past quarter’s continued achievement is testament to this fact. Heading into the second half of the year, we are gaining momentum in several key areas, including reaching our ultimate sales licensing goal, continued cultivation success, enhancement of our genetics portfolio, and expanded near-term and long-term capacity.”
Mr. Malnarich added: “Our board, executive, and operating team are excited about our momentum heading into Q3, and we are motivated to progress toward our goals of achieving our sales license and commercial launch."
Licensing Update
Experion’s initial sales licensing goal is to attain the License to Distribute, enabling the launch of commercial distribution and starting materials. To this end, Experion applied for several license amendments in Q2, including an amendment to sell starter material (submitted April 2018), and an amendment to sell wholesale dried flower (submitted May 2018).
Having successfully completed its Annual Inspection by Health Canada in May 2018, Experion only needs to complete its final inspection specific to each sales amendment.
Cultivation Update
Obtaining its License to Produce in August 2017, Experion began cultivation in January 2018. During the second quarter, Experion completed its first harvest (late March 2018), one of two prerequisite harvests to obtain sales license approval, and completed the second prerequisite harvest in April 2018. Independent test results have since cleared the harvested and cured product establishing saleable inventory once a sales license has been issued.
Expansion Update
Experion’s existing operation at its indoor facility in Mission, BC involves cultivation within a dedicated, pharma grade production space. In May 2018, Experion applied for approval to convert a portion of the current non-production indoor space into cultivation space. This conversion will result in an increase of 20% in total production space.
Experion’s Phase 2 expansion involves construction of two acres of purpose-built greenhouse canopy on the existing property in Mission, BC. Preparation for this expansion continued in the second quarter of fiscal 2018 with site clearing completed in the period.
Genetics Update
One of Experion’s strategic objectives is to build an industry leading genetics portfolio. To this end, Experion was granted its first import permit from Health Canada during the second quarter and received its first seed order (April 2018), increasing its strain selection from 2 to 27 varieties. In May 2018, Experion received a second import permit from Health Canada, and placed a follow-on seed order, which upon delivery (expected July 2018) will further increase Experion’s strain selection from 27 to 44 varieties.
Furthering its genetics objective will require Experion to build upon its research relationships, and has engaged several research institutes to discuss proprietary strain and IP development allowing the Company to expand its R&D interest outside of its local region.
Commercial Distribution Update
During the second quarter, Viridium entered into discussions with prospective wholesale buyers, domestically and internationally, in anticipation of the launch of Experion’s commercial distribution efforts, and the advent of the recreational market in Canada, later in 2018. While discussions are in preliminary stages, the Company believes that the demand for its product will outstrip the Company’s capacity to supply.
About Viridium
Viridium Pacific Group Ltd. is a biotech innovation company based in British Columbia, and the parent company of operating subsidiaries involved in horticultural production (Experion Biotechnologies), property development (Fish Trap Ventures Ltd.), and human resource management (Stave Lake Services Ltd.). Experion Biotechnologies Inc. is a Health Canada licensed producer of cannabis, which operates in an 8,300 square-foot indoor facility outside of Mission, BC.
More information about Viridium can be found under the Company's profile on SEDAR at www.sedar.com.
For further information:
VIRIDIUM PACIFIC GROUP LTD.
Jarrett Malnarick
Chief Executive Officer
Viridium Pacific Group Ltd.
+1 (604) 837-8688
Disclosure
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this Release.
This press release contains forward-looking information within the meaning of Canadian securities laws. Although the Company believes that such information is reasonable, it can give no assurance that such expectations will prove to be correct.
Forward looking information is typically identified by words such as: believe, expect, anticipate, intend, estimate, forecast, postulate and similar expressions, or are those, which, by their nature, refer to future events. The Company cautions investors that any forward-looking information provided by the Company are not guarantees of future results or performance, and that actual results may differ materially from those in forward looking information as a result of various factors, including, but not limited to: the state of the financial markets for the Company's equity securities; recent market volatility; the Company's ability to raise the necessary capital or to be fully able to implement its business strategies; the risks identified in the Filing Statement, and other risks and factors that the Company is unaware of at this time. The reader is referred to the Filing Statement dated September 25, 2017 and/or the most recent annual and interim Management's Discussion and Analysis for a more complete discussion of such risk factors and their potential effects, copies of which may be accessed through the Company page on SEDAR at www.sedar.com.
To view the original release, please click here
Source: Viridium Pacific Group Ltd. (TSX Venture:VIR, OTC Bulletin Board:MRRBF)To follow Viridium Pacific Group Ltd. on your favorite social media platform or financial websites, please click on the icons below.
Maximum News Dissemination by FSCwire. https://www.fscwire.com
Copyright © 2018 FSCwire